Download PDF
Semin Liver Dis 2008; 28(4): 427-433
DOI: 10.1055/s-0028-1091986
© Thieme Medical Publishers

Effects of Weight Loss on Nonalcoholic Fatty Liver Disease

Nila Rafiq1 , Zobair M. Younossi1
  • 1Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, Virginia
Further Information

Publication History

Publication Date:
27 October 2008 (online)

    Permissions and Reprints

ABSTRACT

Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases worldwide, affecting men, women, and children. This is due, in part, to the obesity epidemic, which is associated with increased prevalence of NAFLD. The NAFLD spectrum ranges from simple steatosis to nonalcoholic steatohepatitis (NASH), which is the potentially progressive form. NAFLD is associated with metabolic syndrome and insulin resistance. Treatment recommendations include weight reduction through both diet and physical activity, and weight-loss surgery for extreme obesity. Most medical regimens target components of the metabolic syndrome or oxidative stress associated with the pathogenesis of NASH. These include antiobesity regimens, insulin sensitizers, antihyperlipidemics, and antioxidants. Bariatric surgery is effective for achieving and maintaining weight loss and reversing the complications of metabolic syndrome. On the other hand, the literature lacks well-designed, randomized control trials that assess the efficacy of anti-obesity regimens on histologic and long-term outcomes of NAFLD.

KEYWORDS

Nonalcoholic fatty liver disease (NAFLD) - nonalcoholic steatohepatitis (NASH) - weight loss

REFERENCES

  • 1 World Health Organization .Obesity and overweight. Available at: http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/ Accessed December 10, 2007
    Google Scholar
  • 2 Obesity Action Coalition .Obesity. Available at: http://www.obesityaction.org/aboutus/mission.php Accessed January 19, 2008
    Google Scholar
  • 3 Centers for Disease Control and Prevention .Overweight and obesity. Available at: http://www.cdc.gov/nccdphp/dnpa/obesity/index.htm Accessed December 10, 2007
    Google Scholar
  • 4 Bouneva I, Kirby D. Management of nonalcoholic fatty liver disease: weight control.  Clin Liver Dis. 2004;  8(3) 693-713
    CrossrefPubMedGoogle Scholar
  • 5 Centers for Disease Control and Prevention .Diabetes and trends. Available at: http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm Accessed January 18, 2008
    Google Scholar
  • 6 Wanless I R, Lentz J S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors.  Hepatology. 1990;  12 1106-1110
    CrossrefPubMedGoogle Scholar
  • 7 Ong J P, Younossi Z M. Epidemiology and natural history of NAFLD and NASH.  Clin Liver Dis. 2007;  11(1) 1-16
    CrossrefPubMedGoogle Scholar
  • 8 Ong J P, Pitts A, Younossi Z M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease.  J Hepatol. 2008;  49 608-612
    CrossrefPubMedGoogle Scholar
  • 9 Solga S, Alkhuraishe A R, Clark J M et al.. Dietary composition and nonalcoholic fatty liver disease.  Dig Dis Sci. 2004;  49 1578-1583
    CrossrefPubMedGoogle Scholar
  • 10 Huang M A, Greenson J K, Chao C et al.. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study.  Am J Gastroenterol. 2005;  100 1072-1081
    CrossrefPubMedGoogle Scholar
  • 11 Hernandez R, Martinez-Lara E, Canuelo A et al.. Steatosis recovery after treatment with a balanced sunflower or olive oil-based diet: involvement of perisinusoidal stellate cells.  World J Gastroenterol. 2005;  11 7480-7485
    PubMedGoogle Scholar
  • 12 Lanza-Jacoby S, Smythe C, Phetteplace H, Tabares A. Adaptation to a fish oil diet before inducing sepsis in rats prevents fatty infiltration of the liver.  JPEN J Parenter Enteral Nutr. 1992;  16 353-358
    CrossrefPubMedGoogle Scholar
  • 13 Lai H S, Lin W H, Chen P R, Wu H C, Lee P H, Chen W J. Effects of high-fiber diet on hepatocyte apoptosis and liver regeneration after partial hepatectomy in rats with fatty liver.  JPEN J Parenter Enteral Nutr. 2005;  29 401-407
    CrossrefPubMedGoogle Scholar
  • 14 Samaha F F, Iqbal N, Seshadri P et al.. A low-carbohydrate as compared with a low-fat diet in severe obesity.  N Engl J Med. 2003;  348 2074-2081
    CrossrefPubMedGoogle Scholar
  • 15 Stern L, Iqbal N, Seshadri P et al.. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial.  Ann Intern Med. 2004;  140 778-785
    PubMedGoogle Scholar
  • 16 Dansinger M L, Gleason J A, Griffith J L, Selker H P, Schaefer E J. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial.  JAMA. 2005;  293 43-53
    CrossrefPubMedGoogle Scholar
  • 17 Stewart K J, Bacher A C, Turner K et al.. Exercise and risk factors associated with metabolic syndrome in older adults.  Am J Prev Med. 2005;  28 9-18
    CrossrefPubMedGoogle Scholar
  • 18 Gauthier M S, Couturier K, Latour J G, Lavoie J M. Concurrent exercise prevents high-fat-diet-induced macrovesicular hepatic steatosis.  J Appl Physiol. 2003;  94 2127-2134
    PubMedGoogle Scholar
  • 19 Ueno T, Sugawara H, Sujaku K et al.. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver.  J Hepatol. 1997;  27(1) 103-107
    CrossrefPubMedGoogle Scholar
  • 20 Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients.  Gastroenterology. 1990;  99(5) 1408-1413
    PubMedGoogle Scholar
  • 21 Clark J M. Weight loss as a treatment for nonalcoholic fatty liver disease.  J Clin Gastroenterol. 2006;  40(suppl 1) S39-S43
    PubMedGoogle Scholar
  • 22 Krempf M, Louvet J P, Allanic H et al.. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity.  Int J Obes Relat Metab Disord. 2003;  27 591-597
    CrossrefPubMedGoogle Scholar
  • 23 Harrison S A, Fincke C, Helinski D et al.. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients.  Aliment Pharmacol Ther. 2004;  20 623-628
    CrossrefPubMedGoogle Scholar
  • 24 Hatzitolios A, Savopoulos C, Lazaraki G et al.. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia.  Indian J Gastroenterol. 2004;  23(4) 131-134
    PubMedGoogle Scholar
  • 25 Sabuncu T, Nazligul Y, Karaoglanoglu M et al.. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis.  Rom J Gastroenterol. 2003;  12 189-192
    PubMedGoogle Scholar
  • 26 Gary-Bobo M, Elachouri G, Gallas J F et al.. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats.  Hepatology. 2007;  46 122-129
    CrossrefPubMedGoogle Scholar
  • 27 Van Gaal L F, Rissanen A M, Scheen A J, Ziegler O, Rossner S. RIO-Europe Study Group . Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.  Lancet. 2005;  365 1389-1397
    CrossrefPubMedGoogle Scholar
  • 28 Kakafika A I, Mikhailidis D P, Karagiannis A, Athyros V G. The role of endocannabinoid system blockade in the treatment of the metabolic syndrome.  J Clin Pharmacol. 2007;  47(5) 642-652
    PubMedGoogle Scholar
  • 29 Rucker D, Padwal R, Li S K, Curioni C, Lau D C. Long term pharmacotherapy for obesity and overweight: updated meta-analysis.  BMJ. 2007;  335(7631) 1194-1199
    CrossrefPubMedGoogle Scholar
  • 30 Dixon J B. Surgical treatment for obesity and its impact on non-alcoholic steatohepatitis.  Clin Liver Dis. 2007;  11(1) 141-154
    CrossrefPubMedGoogle Scholar
  • 31 Maggard M A, Shugarman L R, Suttorp M et al.. Meta-analysis: surgical treatment of obesity.  Ann Intern Med. 2005;  142(7) 547-559
    CrossrefPubMedGoogle Scholar
  • 32 Mun E C, Tavakkolizadeh A. Surgical management of severe obesity. Available at: http://www.utdol.com/utd/content/topic.do?topicKey=obesity/6916&selectedTitle=3~150&source=search_result Accessed January 20, 2008
    Google Scholar
  • 33 Rucker Jr R D, Horstmann J, Schneider P D et al.. Comparisons between jejunoileal and gastric bypass operations for morbid obesity.  Surgery. 1982;  92(2) 241-249
    PubMedGoogle Scholar
  • 34 Hocking M P, Davis G L, Franzini D A et al.. Long-term consequences after jejunoileal bypass for morbid obesity.  Dig Dis Sci. 1998;  43(11) 2493-2499
    PubMedGoogle Scholar
  • 35 Kral J G, Thung S N, Biron S et al.. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis.  Surgery. 2004;  135(1) 48-58
    CrossrefPubMedGoogle Scholar
  • 36 Luyckx F H, Desaive C, Thiry A et al.. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty.  Int J Obes Relat Metab Disord. 1998;  22(3) 222-226
    CrossrefPubMedGoogle Scholar
  • 37 Silverman E M, Sapala J A, Appelman H D. Regression of hepatic steatosis in morbidly obese persons after gastric bypass.  Am J Clin Pathol. 1995;  104(1) 23-31
    PubMedGoogle Scholar
  • 38 Mattar S G, Velcum L M, Rabinovitz M et al.. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome.  Ann Surg. 2005;  242(4) 610-617
    PubMedGoogle Scholar
  • 39 Liu X, Laxenby A J, Clements R H, Jhala N, Abrams G A. Resolution of nonalcoholic steatohepatitis after gastric bypass surgery.  Obes Surg. 2007;  17 486-492
    CrossrefPubMedGoogle Scholar
  • 40 Clark J M, Alkhuraishi A R, Solga S F et al.. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease.  Obes Res. 2005;  13(7) 1180-1186
    CrossrefPubMedGoogle Scholar
  • 41 Furuya Jr C K, de Oliveira C P, de Mello E S et al.. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years.  J Gastroenterol Hepatol. 2007;  22 510-514
    CrossrefPubMedGoogle Scholar
  • 42 Sjostrom L, Narbro K, Sjostrom D et al.. Effects of bariatric surgery on mortality in Swedish obese subjects.  N Engl J Med. 2007;  357 741-751
    CrossrefPubMedGoogle Scholar
  • 43 Dixon J B, Bhathal P S, Hughes N R, O'Brien P E. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss.  Hepatology. 2004;  39(6) 1647-1654
    CrossrefPubMedGoogle Scholar
  • 44 O'Brien P E, Dixon J B, Laurie C et al.. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial.  Ann Intern Med. 2006;  144(9) 625-633
    CrossrefPubMedGoogle Scholar
  • 45 Choudhury J, Sanyal A J. Clinical aspects of fatty liver disease.  Semin Liver Dis. 2004;  24 349-362
    PubMedGoogle Scholar
  • 46 Hedley A A, Ogden C L, Johnson C L, Carroll M D, Curtin L R, Flegal K M. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002.  JAMA. 2004;  291 2847-2850
    CrossrefPubMedGoogle Scholar
  • 47 Franzese A, Vajro P, Argenziano A et al.. Liver involvement in obese children: ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population.  Dig Dis Sci. 1997;  42 1428-1432
    CrossrefPubMedGoogle Scholar
  • 48 Tominaga K, Kurata J H, Chen Y K et al.. Prevalence of fatty liver in Japanese children and relationship to obesity: an epidemiological ultrasonographic survey.  Dig Dis Sci. 1995;  40 2002-2009
    PubMedGoogle Scholar
  • 49 Nobili V, Marcellini M, Devito R et al.. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice.  Hepatology. 2006;  44(2) 458-465
    CrossrefPubMedGoogle Scholar
  • 50 Hickman I J, Clouston A D, Macdonald G A et al.. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C.  Gut. 2002;  51 89-94
    CrossrefPubMedGoogle Scholar
  • 51 Hickman I J, Jonsson J R, Prins J B et al.. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvement in alanine aminotransferases, fasting insulin and quality of life.  Gut. 2004;  53(3) 413-419
    CrossrefPubMedGoogle Scholar

Zobair M YounossiM.D. M.P.H. 

Center for Liver Diseases, Inova Fairfax Hospital

3300 Gallows Road, Falls Church, VA 22042

Email: zobair.younossi@inova.org

      >